当前位置: X-MOL 学术Schmerz › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Medizinische Versorgung mit Cannabis – die Rechtslage klärt sich
Der Schmerz ( IF 1 ) Pub Date : 2019-09-02 , DOI: 10.1007/s00482-019-00410-7
Oliver Tolmein

BACKGROUND Since March 2017 the law amending narcotics and other legal regulations has made it possible for doctors to prescribe cannabis and cannabis-derived medicines. The introduction of § 31 para 6 of the Social Code Book V (SGB V) allows that patients can be treated with cannabis-derived medicines at the expense of the statutory health insurance if they have a severe illness. COURT DECISIONS The law requires the approval of a prescription of cannabis for medical purposes by the health insurance before the granting of benefits. Due to denied permission, numerous cases are pending before the social tribunals. The article presents which legal issues are decided and why there is still no case law from the Federal Social Court on the essential questions. OUTLOOK The possibility of prescribing cannabis as medicine at the expense of the health insurance is an important advance in social law. The § 31 para 6 SGB V should be evaluated as soon as possible. The provisions of SGB V for the reimbursement of off-label treatment should be harmonized with § 31 para 6 SGB V.

中文翻译:

大麻的医疗供应 - 法律情况得到澄清

背景 自 2017 年 3 月以来,修订麻醉品的法律和其他法律法规使医生能够开出大麻和大麻衍生药物。社会法典 V (SGB V) 第 31 条第 6 段的引入允许患者在患有严重疾病的情况下接受大麻衍生药物治疗,但需支付法定健康保险。法院判决 法律要求在发放福利之前,健康保险必须批准用于医疗目的的大麻处方。由于被拒绝许可,许多案件正在社会法庭审理。本文介绍了决定哪些法律问题,以及为什么联邦社会法院仍然没有关于基本问题的判例法。展望 以牺牲健康保险为代价将大麻作为药物的可能性是社会法的一项重要进步。应尽快评估第 31 条第 6 款 SGB V。SGB V 中关于标签外治疗报销的规定应与 SGB V § 31 第 6 段相协调。
更新日期:2019-09-02
down
wechat
bug